The U.S. Food and Drug Administration today announced that it is updating the warning labels required on three gadolinium-based MRI contrast agents sold in the U.S. due to the risk of nephrogenic systemic fibrosis.
FDA updates warning labels on gadolinium contrast
Sep 8, 2010
Latest in MRI
Radiomics models based on pituitary MRI predict GHD
October 27, 2025
Trump undergoes MRI exam
October 27, 2025



.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=100&q=70&w=100)
.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=167&q=70&w=250)











